Online inquiry

IVTScrip™ mRNA-Anti-CD3E&TNFRSF17, JNJ-64007957(Cap 0, 5-Methyl-CTP, 120 nt-poly(A))   (CAT#: GTTS-WQ9655MR)

This product GTTS-WQ9655MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 0 & 5-Methyl-CTP. It ecodes the monoclonal antibody that targets CD3E&TNFRSF17 gene. The antibody can be applied in Multiple myeloma (MM) research.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP
5' Cap Cap 0
Species Homo sapiens; Chimeric
RefSeq NM_000733.4; NM_001192.3
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 916; 608
UniProt ID P07766; Q02223
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-CD3E&TNFRSF17, JNJ-64007957(Cap 0, 5-Methyl-CTP, 120 nt-poly(A)) (GTTS-WQ9655MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ9214MR IVTScrip™ mRNA-Anti-MS4A1, IMMU-106(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA IMMU-106
GTTS-WQ8856MR IVTScrip™ mRNA-Anti-MS4A1, IDEC-C2B8(Cap 1, 2-Thio-UTP, 120 nt-poly(A)) mRNA IDEC-C2B8
GTTS-WQ4503MR IVTScrip™ mRNA-Anti-CXCL10, BMS-936557(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA BMS-936557
GTTS-WQ2919MR IVTScrip™ mRNA-Anti-ERBB3, AMG888(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA AMG888
GTTS-WQ4553MR IVTScrip™ mRNA-Anti-CXCR4, BMS-936564(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA BMS-936564
GTTS-WQ6652MR IVTScrip™ mRNA-Anti-ITGAV, DI-17E6(Cap 1, 2-Thio-UTP, 120 nt-poly(A)) mRNA DI-17E6
GTTS-WQ2669MR IVTScrip™ mRNA-Anti-TNFRSF10B, AMG 655(Cap 0, 2-Thio-UTP, 30 nt-poly(A)) mRNA AMG 655
GTTS-WQ7687MR IVTScrip™ mRNA-Anti-CD3E&MS4A1, GEN3013(Cap 0, 5-Methyl-CTP, 120 nt-poly(A)) mRNA GEN3013
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW